本論文分為兩部份，第一部份為人體尿液中安非他命之檢測，安非他
命在人體內並不會百分之百被吸收及代謝，因此在排泄的尿液中約有２０
％∼３０％的安非他命未被代謝或以原型代謝的型式存在，再加上尿液取
得容易且其量充足，所以一般而言，藥檢單位對人的檢驗皆選擇尿液為分
析樣品．本方法之特點在於去蛋白質和衍生化反應是同時進行，先將尿液
試樣和溶於有機溶劑之單斯氯(Dansyl Chloride, DanCl)反應，再利用高
效能液相層析／螢光檢測器來偵測樣品中安非他命-單斯氯(Amphetamine-
Dansyl Chloride, AP-DanCl)所測得的偵測極限為6000ng/L，與文獻上所
舉之GC/MS 的偵測極限1100ng/L和其他液相層析法比較之，不但更靈敏且
更簡易．　　第二部份的分析樣品為清醒大白鼠的腦中透析液，目的是利
用先進的微量透析技術，觀察將安非他命注射入大白鼠體內後，安非他命
在其腦脊髓液中之濃度隨時間變化的情形，以了解安非他命的藥理動力學
．因為所得試樣量很少(約0.02mL)，且安非他命的濃度很低，不易用GC/
MS 或其他方法檢測，我們利用發展之高效能液相層析／螢光衍生法成功
地檢測大白鼠腦脊髓液中的安非他命濃度之變化．
　　A simple HPLC assay for the determination of amphetamine in
urine withminimal sample preparation is described. This method
involves direct additionof human urine sample into acetone/
dansyl chloride solution for simultaneousprotein precipitation
and fluorescence derivatization. Amphetamine was derivatized by
dansyl chloride in urine and then measured by HPLC with
fluorescence detection. It eliminates extraction procedures
often required byother LC or GC methods. The effects of pH,
temperature and reaction time onderivatization reaction in urine
were investigated. The detection limit andlinearity associated
with this assay were discussed.　　In addition, this method was
also applied to the analysis of amphetaminein microdialysate for
pharmacology application.